Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 917 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR Want to learn more about Sulforaphanes? December 4, 2020 ESMO Publishes First Guidance on the Safe Use of Large Language... October 18, 2025 Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with... June 11, 2026 Celebrating 10 years of partnership with NIVEA Sun October 14, 2022 Load more HOT NEWS Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into... The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Foodie Friday: Watermelon Fruit Pizza One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among...
